Nicholas J. Short

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 325 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi et al. · Journal of Clinical Oncology · 2021 · 321 citations · Full text

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

Elias Jabbour, Nicholas J. Short, Farhad Ravandi et al. · The Lancet Haematology · 2018 · 263 citations · Full text

Hematological Malignancy, First-line Therapy, Oncology +8

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

Koji Sasaki, Farhad Ravandi, Tapan M. Kadia et al. · Cancer · 2021 · 255 citations · Full text

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Nicholas J. Short, Elias Jabbour, Koji Sasaki et al. · Blood · 2016 · 246 citations · Full text